Prognostic relevance of topoisomerase II α and minichromosome maintenance protein 6 expression in colorectal cancer.
Aged
Biomarkers, Tumor
/ metabolism
Cell Proliferation
Colon
/ pathology
Colorectal Neoplasms
/ mortality
DNA Topoisomerases, Type II
/ metabolism
Disease-Free Survival
Female
Humans
Male
Middle Aged
Minichromosome Maintenance Complex Component 6
/ metabolism
Poly-ADP-Ribose Binding Proteins
/ metabolism
Prognosis
Rectum
/ pathology
Retrospective Studies
Survival Analysis
Colorectal cancer
Minichromosome maintenance protein 6
Prognostic marker
Proliferative proteins
Topoisomerase II α
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
09 May 2019
09 May 2019
Historique:
received:
01
10
2018
accepted:
23
04
2019
entrez:
11
5
2019
pubmed:
11
5
2019
medline:
12
9
2019
Statut:
epublish
Résumé
Despite rising incidence rates of colorectal malignancies, only a few prognostic tools have been implemented in proven clinical routine. Cell division and proliferation play a significant role in malignancies. In terms of colorectal cancer, the impact of proliferation associated proteins is controversially debated. The aim of our study was to examine the expression of topoisomerase II α and minichromosome maintenance protein 6 and to correlate these findings with the clinical data. Tissue samples of 619 patients in total were stained using the antibodies Ki-S4 and Ki-MCM6 targeting topoisomerase II α as well as minichromosome maintenance protein 6. The median rate of proliferation was correlated with clinical and follow up data. The expression rate of minichromosome maintenance protein 6 is significantly higher than the proportion of topoisomerase II α in tumour cells (p < 0.001). A high expression of both proteins coincides with a beneficial outcome for the patient, indicating a favourable prognostic marker (p < 0.001 and p = 0.008). We have demonstrated that high expression rates of proliferative markers is linked to a beneficial patient outcome. According to the general opinion, a high expression rate correlates with a poor patient outcome. In this study, we were able to refute this assertion.
Sections du résumé
BACKGROUND
BACKGROUND
Despite rising incidence rates of colorectal malignancies, only a few prognostic tools have been implemented in proven clinical routine. Cell division and proliferation play a significant role in malignancies. In terms of colorectal cancer, the impact of proliferation associated proteins is controversially debated. The aim of our study was to examine the expression of topoisomerase II α and minichromosome maintenance protein 6 and to correlate these findings with the clinical data.
METHODS
METHODS
Tissue samples of 619 patients in total were stained using the antibodies Ki-S4 and Ki-MCM6 targeting topoisomerase II α as well as minichromosome maintenance protein 6. The median rate of proliferation was correlated with clinical and follow up data.
RESULTS
RESULTS
The expression rate of minichromosome maintenance protein 6 is significantly higher than the proportion of topoisomerase II α in tumour cells (p < 0.001). A high expression of both proteins coincides with a beneficial outcome for the patient, indicating a favourable prognostic marker (p < 0.001 and p = 0.008).
CONCLUSIONS
CONCLUSIONS
We have demonstrated that high expression rates of proliferative markers is linked to a beneficial patient outcome. According to the general opinion, a high expression rate correlates with a poor patient outcome. In this study, we were able to refute this assertion.
Identifiants
pubmed: 31072339
doi: 10.1186/s12885-019-5631-3
pii: 10.1186/s12885-019-5631-3
pmc: PMC6507179
doi:
Substances chimiques
Biomarkers, Tumor
0
Poly-ADP-Ribose Binding Proteins
0
MCM6 protein, human
EC 3.6.4.12
Minichromosome Maintenance Complex Component 6
EC 3.6.4.12
DNA Topoisomerases, Type II
EC 5.99.1.3
TOP2A protein, human
EC 5.99.1.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
429Références
J Pathol. 1999 Jan;187(2):207-16
pubmed: 10365096
Breast Cancer Res Treat. 1999 May;55(1):61-71
pubmed: 10472780
Annu Rev Biochem. 2001;70:369-413
pubmed: 11395412
Lab Invest. 2001 Aug;81(8):1163-5
pubmed: 11502867
Hum Pathol. 2002 Nov;33(11):1114-9
pubmed: 12454816
J Clin Oncol. 2003 Jan 15;21(2):241-50
pubmed: 12525515
Clin Cancer Res. 2003 Apr;9(4):1406-11
pubmed: 12684412
Leukemia. 2004 Jul;18(7):1200-6
pubmed: 15116121
Am J Clin Pathol. 2004 Dec;122(6):912-8
pubmed: 15539383
Br J Cancer. 2005 Oct 17;93(8):939-45
pubmed: 16189522
Dig Dis Sci. 2009 Feb;54(2):282-91
pubmed: 18465232
Cell. 1990 Jun 1;61(5):759-67
pubmed: 2188735
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
Gut Liver. 2014 Jan;8(1):13-23
pubmed: 24516696
Anticancer Res. 2014 Aug;34(8):4569-75
pubmed: 25075101
Mol Med Rep. 2015 Mar;11(3):1566-72
pubmed: 25384676
Am J Cancer Res. 2014 Dec 15;5(1):52-71
pubmed: 25628920
Ann Surg Oncol. 2015 Dec;22(13):4344-51
pubmed: 25777091
J Clin Pathol. 2016 Mar;69(3):209-14
pubmed: 26281861
Oncotarget. 2016 Feb 2;7(5):6281-93
pubmed: 26823390
Future Oncol. 2017 Apr;13(9):843-857
pubmed: 28075166
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Oncotarget. 2017 Jul 25;8(30):50273-50283
pubmed: 28488584
Urol Oncol. 2017 Aug;35(8):499-506
pubmed: 28648414
Genes Dev. 2017 Jun 1;31(11):1073-1088
pubmed: 28717046
Hum Pathol. 2018 Jan;71:20-29
pubmed: 28782638
Cancer Biol Ther. 2018 Mar 4;19(3):153-159
pubmed: 29261002
BMC Cancer. 2018 Mar 27;18(1):331
pubmed: 29587760
Onco Targets Ther. 2018 Aug 20;11:5025-5034
pubmed: 30174440
J Immunol. 1984 Oct;133(4):1710-5
pubmed: 6206131
Pathologe. 1994 Dec;15(6):345-9
pubmed: 7855103
J Histochem Cytochem. 1997 Feb;45(2):251-63
pubmed: 9016314